TRIAL IN PROGRESS: PHASE 1 FIRST-IN-HUMAN STUDY OF XL092 ADMINISTERED ALONE OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

被引：1
|
作者：
Patnaik, Amita [1 ]
Subbiah, Vivek [2 ]
Shapiro, Geoffrey [3 ]
Pal, Sumanta [4 ]
Agarwal, Neeraj [5 ]
Wentzel, Kristopher [6 ]
Li, Jing [7 ]
McIlvaine, Elizabeth [7 ]
Waldes, Jana [7 ]
Cha, Edward [8 ]
Tadjalli-Mehr, Keyvan [9 ]
Sharma, Manish [10 ]
机构：
[1] START, San Antonio, TX USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Utah, Salt Lake City, UT USA
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Exelixis Inc, Alameda, CA USA
[8] Genentech Inc, Singapore, CA USA
[9] Healthcare Business Merck KGaA, Darmstadt, Germany
[10] START Midwest, Grand Rapids, MI USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
513
引用
收藏
页码：A544 / A544
页数：1
相关论文
共 50 条
  • [1] A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
    Sharma, Manish
    Subbiah, Vivek
    Shapiro, Geoffrey
    Pal, Sumanta K.
    Agarwal, Neeraj
    Wentzel, Kristopher
    Hazra, Saswati
    Vora, Rashmi
    Waldes, Jana
    Cha, Edward
    Mehr, Keyvan Tadjalli
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
    Sharma, M. R.
    Subbiah, V.
    Shapiro, G.
    Pal, S. K.
    Agarwal, N.
    Wentzel, K.
    Fang, B.
    Zhang, N.
    Schwickart, M.
    Wang, Z.
    Curran, D.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S760
  • [3] A MULTICOHORT PHASE 1B STUDY (STELLAR-002) OF XL092 IN COMBINATION WITH IMMUNOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
    Mcgregor, Bradley
    Choueiri, Toni
    Shah, Neil
    Bajaj, Aung
    Chahoud, Jad
    O'Neil, Bert
    Michalski, Joel
    Garmezy, Benjamin
    Jin, Lixian
    Aziz, Usman
    Xu, Fiona
    Motzer, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A775 - A775
  • [4] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
    Johnson, Melissa
    Ulahannan, Susanna
    Vandross, Andrae
    Park, Haeseong
    Faoro, Leo
    Faggioni, Raffaella
    Li, Jing
    Chang, Yu-Lin
    Uttamsingh, Shailaja
    Tolcher, Anthony
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.
    Powderly, John
    Shimizu, Toshio
    LoRusso, Patricia
    Razak, Albiruni
    Miller, Kathy
    Balar, Arjun
    Bruix, Jordi
    Michel, Loren
    Blaney, Martha
    Guan, Xiaowen
    Lacy, Susan
    Lally, Satwant
    Lambert, Stacie
    Leibman, Rachel
    Vosganian, Gregory
    Golan, Talia
    Tolcher, Anthony
    CANCER RESEARCH, 2021, 81 (13)
  • [6] A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors
    Choueiri, Toni K.
    McGregor, Bradley Alexander
    Shah, Neil J.
    Bajaj, Aung
    Chahoud, Jad
    O'Neil, Bert
    Michalski, Joel
    Garmezy, Benjamin
    Jin, Lixian
    Oliver, Jennifer Wright
    Wang, Yijia
    Tayama, Darren
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors
    Powderly, John D.
    Sullivan, Ryan J.
    Gutierrez, Martin
    Khattak, Adnan
    Thomas, Sajeve Samuel
    Jimeno, Antonio
    Pascarella, Stephanie
    Zhu, Lili
    Morrissey, Manju
    Meehan, Robert S.
    Barlaskar, Ferdous
    Brown, Michelle
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
    Papadopoulos, Kyriakos P.
    Ahnert, Jordi Rodon
    Khushman, Moh'd M.
    Sharma, Sunil
    Pelster, Meredith
    Cecchini, Michael
    Kummar, Shivaani
    Choi, Minjung
    Akella, Lalith V.
    Garofalo, Amanda
    Yu, Ziyang
    Iyer, Varsha
    Nguyen, Marie Huong
    Orford, Keith W.
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A phase 1/2, first-in-human study of STX-478 monotherapy or in combination with fulvestrant in patients with breast cancer or other advanced solid tumors (trial in progress)
    Montero, Alberto
    Orr, Douglas
    Munster, Pamela
    LoRusso, Patricia
    Jhaveri, Komal
    Pluard, Timothy
    Winer, Ira
    Streit, Michael
    Patterson, Monica
    Roberts, Simon
    Corsi-Travali, Stefani
    Ewert, Courtney
    Juric, Dejan
    CANCER RESEARCH, 2024, 84 (09)
  • [10] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
12345